-
公开(公告)号:US20050084840A1
公开(公告)日:2005-04-21
申请号:US10502279
申请日:2003-01-22
申请人: Hideki Endoh , Ryosuke Nakano , Eiji Kurosaki , Miyuki Kato , Hiroyuki Yokota , Kazunori Inabe
发明人: Hideki Endoh , Ryosuke Nakano , Eiji Kurosaki , Miyuki Kato , Hiroyuki Yokota , Kazunori Inabe
IPC分类号: A61P3/10 , C12N1/19 , C12N1/21 , C12N15/10 , C12N15/12 , C12Q1/68 , G01N33/566 , C12N1/18 , C12N15/74 , C12Q1/00
CPC分类号: G01N33/566 , C12N15/1055 , C12Q1/6897 , G01N2333/70567
摘要: Disclosing a method for screening a protein interactive with PPAR in a ligand-dependent manner, works as a useful tool for screening a drug ameliorating insulin resistance. By the method, ECHLP as a main action ligand-dependent PPAR binding molecule, FLJ13111 as a main action ligand-selective factor interactive with PPARγ and AOP2 as an adverse action ligand-dependent PPAR binding molecule were obtained. By using ECHLP interactive with PPAR, FLJ13111 interactive with PPAR and AOP2 interactive with PPAR, a screening system for a drug ameliorating insulin resistance is constructed and disclosed, the drug giving selectively the main action with no occurrence of the adverse action. Additionally, a method for producing a pharmaceutical composition for ameliorating insulin resistance is disclosed, which contains as the active component, a promoting agent of the main action through PPAR, an agonist specific to the main action through PPAR, an inhibitor of ECHLP interactive with PPAR to promote the main action through PPAR, a substance suppressing the adverse action through PPARγ, an inhibitor of AOP2 interactive with PPAR to suppress the adverse action through PPARγ, an activating agent of FLJ13111 interactive with PPAR to promote the main action through PPAR or an activator of FLJ13111 expression.
摘要翻译: 披露以配体依赖的方式筛选与PPAR相互作用的蛋白质的方法,其作为筛选改善胰岛素抵抗的药物的有用工具。 通过该方法,获得了作为主要作用配体依赖性PPAR结合分子的ECHLP,FLJ13111作为与PPARgamma和AOP2作为不利作用配体依赖性PPAR结合分子相互作用的主要作用配体选择性因子。 通过使用ECHLP与PPAR交互,FLJ13111与PPAR和AOP2交互式与PPAR交互,构建并公开了改善胰岛素抵抗的药物筛选系统,该药物选择性地给予主要作用,不发生不良反应。 另外,公开了一种制备用于改善胰岛素抵抗的药物组合物的方法,其包含通过PPAR作为主要作用的主要作用的促进剂,通过PPAR主要作用的激动剂,与PPAR相互作用的ECHLP抑制剂 通过PPAR促进PPAR的主要作用,PPARgamma是与PPAR相互作用的AOP2抑制剂,通过PPARgamma的抑制剂来抑制不良反应,PPARgamma是与PPAR相互作用的FLJ13111激活剂,通过PPAR或激活剂促进主要作用 的FLJ13111表达。
-
公开(公告)号:US20070128691A1
公开(公告)日:2007-06-07
申请号:US10575253
申请日:2004-10-08
申请人: Ryosuke Nakano , Mitsuo Satoh , Shigeru Iida , Miho Inoue , Machi Kusunoki , Satoko Kinoshita , Naoko Ohnuki
发明人: Ryosuke Nakano , Mitsuo Satoh , Shigeru Iida , Miho Inoue , Machi Kusunoki , Satoko Kinoshita , Naoko Ohnuki
CPC分类号: C12N5/0018 , C12N2500/92 , C12N2500/95 , C12N2510/00 , C12N2510/02
摘要: Development of a host cell capable of producing a glycoprotein composition such as an antibody composition which is useful in development of medicaments is desired. The present invention provides a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium and a process for producing a glycoprotein composition using the cell.
摘要翻译: 需要开发能够产生可用于开发药物的糖蛋白组合物如抗体组合物的宿主细胞。 本发明提供一种细胞,其中编码与糖链修饰相关的酶的基因组基因,其中岩藻糖的1位通过复合型N中的α-键与还原末端的N-乙酰葡糖胺的6-位结合 - 糖苷连接的糖链被敲除,其中细胞在无血清培养基中归化,以及使用该细胞产生糖蛋白组合物的方法。
-
公开(公告)号:US07268150B2
公开(公告)日:2007-09-11
申请号:US10492347
申请日:2003-07-18
申请人: Masahiko Hayakawa , Kenji Negoro , Satoshi Miyamoto , Takayuki Suzuki , Tatsuya Maruyama , Ryosuke Nakano
发明人: Masahiko Hayakawa , Kenji Negoro , Satoshi Miyamoto , Takayuki Suzuki , Tatsuya Maruyama , Ryosuke Nakano
IPC分类号: A61K31/445 , C07D207/16
CPC分类号: C07D401/12 , C07D207/16 , C07D401/14 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D451/04
摘要: Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.
摘要翻译: 提供了具有优异的二肽基肽酶IV抑制活性的化合物,以及基于胰岛素依赖性糖尿病(1型糖尿病)的活性,特别是对于非胰岛素依赖性糖尿病(2型糖尿病),胰岛素抵抗障碍和 肥胖。
-
公开(公告)号:US20080064726A1
公开(公告)日:2008-03-13
申请号:US11579057
申请日:2005-04-25
IPC分类号: A61K31/4523 , A61P3/10 , C07D221/00
CPC分类号: C07D409/14 , C07D401/12 , C07D405/14
摘要: There is provided a novel pyrrolidine derivative represented by the formula (I) or a salt thereof having an excellent DPP-IV inhibitory activity and an excellent pharmacokinetic. On the basis of the action as such, the compound of the present invention is useful for treatment and/or prevention of insulin-dependent diabetes mellitus (type 1 diabetes mellitus) and particularly for non insulin-dependent diabetes mellitus (type 2 diabetes mellitus), insulin-resistant diseases, obesity, etc. [In the formula, -A- is a single bond, —O—, —S—, —NH— or —N(lower alkyl)-; and —B is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, non-aromatic hetero ring or aromatic hetero ring and each of those groups may be substituted.]
摘要翻译: 提供由式(I)表示的新型吡咯烷衍生物或其具有优异的DPP-IV抑制活性和优异的药代动力学的盐。 基于这样的作用,本发明的化合物可用于治疗和/或预防胰岛素依赖性糖尿病(1型糖尿病),特别是用于非胰岛素依赖性糖尿病(2型糖尿病) ,胰岛素抵抗性疾病,肥胖症等。[式中,-A-为单键,-O - , - S-,-NH-或-N(低级烷基) - 。 并且-B是低级烷基,低级烯基,低级炔基,环烷基,芳基,非芳族杂环或芳族杂环,并且这些基团中的每一个可以被取代。
-
公开(公告)号:US20050176771A1
公开(公告)日:2005-08-11
申请号:US10492347
申请日:2003-07-18
申请人: Masahiko Hayakawa , Kenji Negoro , Satoshi Miyamoto , Takayuki Suzuki , Tatsuya Maruyama , Ryosuke Nakano
发明人: Masahiko Hayakawa , Kenji Negoro , Satoshi Miyamoto , Takayuki Suzuki , Tatsuya Maruyama , Ryosuke Nakano
IPC分类号: A61P3/10 , A61P43/00 , C07D207/16 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D451/04 , C07D471/06 , A61K31/454 , A61K31/416 , A61K31/422
CPC分类号: C07D401/12 , C07D207/16 , C07D401/14 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D451/04
摘要: Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.
摘要翻译: 提供了具有优异的二肽基肽酶IV抑制活性的化合物,以及基于胰岛素依赖性糖尿病(1型糖尿病)的活性,特别是对于非胰岛素依赖性糖尿病(2型糖尿病),胰岛素抵抗障碍和 肥胖。
-
-
-
-